
Keywords: cost-effectiveness; mediastinal lymph node staging; EBUS-TBNA; mediastinoscopy; CAD; Canadian dollar; CRMM; cancer risk management model; EBUS-TBNA; endobronchial ultrasound transbronchial needle aspiration; ICER; incremental cost effectiveness ratio; LN;